Hassan and colleagues performed a retrospective analysis of 81 patients who presented for open cardiac surgery while receiving novel oral anticoagulant (NOAC) therapy. Patients were off NOACs for a median of 4 days (IQR, 3 - 6 days) prior to surgery.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
valve
Bleeding Complications After Use of Novel Oral Anticoagulants in Patients Undergoing Cardiac Surgery
March 26, 2018
March 23, 2018
Patient Care
A teen in Chicago, Illinois, USA, awaiting a heart transplant received the news that a heart was available from his pediatric cardiologist, who dressed up as Chewbacca from Star Wars just for the occasion.